04:56 PM EDT, 09/27/2024 (MT Newswires) -- Poseida Therapeutics ( PSTX ) said late Friday a phase 1 trial of P-BCMA-ALLO1 therapy to treat relapsed or refractory multiple myeloma, a type of cancer, yielded positive data.

The company said data showed an overall response rate of 91% and "compelling" safety results in the 23 "heavily pretreated" patients in an "optimized lymphodepletion arm" called Arm C.

The data were presented Friday at the 21st International Myeloma Society Annual Meeting in Rio de Janeiro.

The investigational off-the-shelf allogeneic CAR-T cell therapy is being developed as part of a broader collaboration with Roche focused on addressing blood cancers, Poseida said.

Poseida shares were down 4% in volatile after-hours trading.

Price: 2.7800, Change: -0.12, Percent Change: -4.14